米哚妥林与伏立康唑双向药物相互作用病例报告
本文报告一例49岁急性髓系白血病女性患者,在诱导化疗后发生侵袭性肺曲霉病,接受标准剂量伏立康唑治疗。加用米哚妥林6天后出现视幻觉,伏立康唑谷浓度升至10.3 mg/L(目标1-5 mg/L),米哚妥林浓度超出预期平均水平6倍。停用米哚妥林并调整伏立康唑剂量后症状迅速缓解。提示两者相互抑制代谢,建议密切临床和TDM监测。
要点
- 米哚妥林与伏立康唑联用可双向抑制代谢,导致两者暴露均升高。
- 伏立康唑谷浓度10.3 mg/L(目标1-5 mg/L)时出现视幻觉等神经毒性。
- 联用期间应密切临床监测并进行治疗药物监测(TDM)。
核心结论
- 米哚妥林与伏立康唑可能相互抑制对方代谢,导致两者暴露增加,需密切监测。
研究设计与样本
- 单例病例报告:49岁急性髓系白血病女性患者,诱导化疗后发生侵袭性肺曲霉病,接受标准剂量伏立康唑治疗。
主要发现
- 加用米哚妥林6天后出现视幻觉,伏立康唑谷浓度10.3 mg/L(目标1-5 mg/L)。
- 同期米哚妥林浓度超出预期平均水平6倍,但未报告安全性问题。
- 停用米哚妥林并调整伏立康唑剂量后,症状迅速缓解且未复发。
关键数值与推荐
- 伏立康唑目标谷浓度1-5 mg/L,本例患者谷浓度10.3 mg/L。
- 米哚妥林浓度超出预期平均水平6倍。
临床怎么用
- 米哚妥林与唑类抗真菌药联用时,应密切临床监测并进行治疗药物监测(TDM)。
局限性
- 仅为单例病例报告,不能确立因果关系或推广至所有患者。
- 米哚妥林作为 perpetrator 的药物相互作用数据仍缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Midostaurin is often prescribed with azole antifungals in patients with leukaemia, either for aspergillosis prophylaxis or treatment. Midostaurin is extensively metabolized by cytochrome (CYP) 3A4. In addition, it inhibits and induces various CYPs at therapeutic concentrations. Thus, midostaurin is associated with a high potential for drug-drug interactions (DDIs), both as a substrate (victim) and as a perpetrator. However, data on midostaurin as a perpetrator of DDIs are scarce, as most pharmacokinetic studies have focused on midostaurin as a victim drug. We report a clinically relevant bidirectional DDI between midostaurin and voriconazole during induction treatment. A 49-year-old woman with acute myeloid leukaemia developed invasive pulmonary aspergillosis after induction chemotherapy. She was treated with voriconazole at standard dosage. Six days after starting midostaurin, she developed visual hallucinations with a concurrent sharp increase in voriconazole blood concentration (Ctrough 10.3 mg L-1 , target Ctrough 1-5 mg L-1 ). Neurotoxicity was considered to be related to voriconazole overexposure. The concentration of midostaurin was concomitantly six-fold above the average expected level, but without safety issues. Midostaurin was stopped and the dosage of voriconazole was adjusted with therapeutic drug monitoring. The evolution was favourable, with quick resolution and no recurrence of visual hallucinations. To our knowledge, this is the first case suggesting that midostaurin and voriconazole reciprocally inhibit each other's metabolism, leading to increased exposure of both. This case highlights the knowledge gap regarding drug-drug interactions between midostaurin and azole antifungals. Close clinical and therapeutic drug monitoring is advised in such cases.
引用
- Haefliger D, Marzolini C, Lamoth F, et al. Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole. Br J Clin Pharmacol. 2023. PMID: 37050863. doi:10.1111/bcp.15743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。